*|MC:SUBJECT|*

View this email in your browser

CLINICAL
TRIALS

WINTER 2020

The following studies are open for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.

For more information or questions about a study, please email [email protected] or call
312-355-5112.

We look forward to serving your patients.

John H. Stewart, IV, MD, MBA
Associate Director, Clinical Sciences
Physician Executive, Oncology Service Line

[email protected]

Browse our list of enrolling clinical trials here

PHONE
312-355-5112

EMAIL
[email protected]

REFER A PATIENT
312-966-6914

cancer.uillinois.edu

UI Cancer Center Investigator Initiated Clinical Trials

Below are unique UI Cancer Center clinical trials designed by our faculty which are currently enrolling patients (click study title for more information):

Breast Cancer
Phase 2 Trial Of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed By Doxorubicin And Cyclophosphamide In Triple Negative Breast Cancer (BRE-01)

PI: Kent Hoskins, MD

Gastrointestinal Cancer
A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)

PI: John Stewart, IV, MD , MBA

Hematologic Malignancies
Phase Ib Study of the Safety and Efficacy Of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia (BTCRC-AML17-113)

PI: John Quigley, MD

UI Cancer Center Clinical Trial Highlights

Breast Cancer
An open-label randomized Phase 2 trial of SAR439859,versus endocrine monotherapy as per physician's choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies (ACT16105)

PI: Oana Danciu, MD

Gastrointestinal Cancer
A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (BTCRC-GI15-015)

PI: Neeta Venepalli, MD

Hematologic Malignancies
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INCB 53914-102)

PI: John Galvin, MD

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV-MF), Or Post Essential Thrombocythemia MF (Post ET-MF) Who Have Failed Ruxolitinib (KRT-232-101)

PI: Irum Khan, MD

Lung Cancer
Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy
(BTCRC-LUN15-017)

PI: Lawrence Feldman, MD

UPCOMING EVENTS

Margaret Foti, PhD, MD (hc) – AACR and the Next Wave of Innovation in Cancer Research and Patient Care
February 27 • 1:30 pm - 2:30 pm
UIC College of Medicine Research Building (COMRB)
Moss Auditorium (Room 1020), 909 S. Wolcott Ave. + Google Map

Dr. Gary Kruh Cancer Research Symposium 2020

April 15, 2020 • 8:00 am - 5:00 pm
UIC Student Center West, Thompson Rooms, 2nd floor
828 S. Wolcott Ave. + Google Map

This annual event, named for former University of Illinois Cancer Center Director Dr. Gary Kruh, brings together cancer researchers, faculty and students to learn more about the latest advancements in cancer research. A student poster competition will also be held. Lunch will be provided. Speaker and event details to come.

Find out more »

The University of Illinois Cancer Center is comprised of physicians and cancer researchers dedicated to pursuing health equity; working with the community in developing research and treatment options; and studying cancer disparities. We are part of the University of Illinois at Chicago and University of Illinois Hospital and Health Sciences System.

UICancerCenter

cancer.uillinois.edu